Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
Main Authors: | , , , |
---|---|
格式: | Journal article |
語言: | English |
出版: |
Elsevier
2020
|
Main Authors: | , , , |
---|---|
格式: | Journal article |
語言: | English |
出版: |
Elsevier
2020
|